Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20126635 | 0.95 | ALDH1A1 (0.34) | ALDH1A1KDM4ESMN1; SMN2TDP1ELANE | |
| SCHEMBL17351857 | 0.95 | ALDH1A1 (0.34) | ALDH1A1KDM4ESMN1; SMN2TDP1ELANE | |
| SCHEMBL15937165 | 0.95 | ALDH1A1 (0.34) | ALDH1A1KDM4ESMN1; SMN2TDP1ELANE | |
| SCHEMBL17351889 | 0.87 | KDM4E (0.34) | ALDH1A1KDM4ESMN1; SMN2TDP1LMNA | |
| SCHEMBL17351840 | 0.86 | GRIN2B (0.31) | ALDH1A1KDM4ESMN1; SMN2TDP1 | |
| SCHEMBL15937173 | 0.86 | GRIN2B (0.31) | ALDH1A1KDM4ESMN1; SMN2TDP1 | |
| SCHEMBL17359164 | 0.85 | — | — | |
| SCHEMBL17359160 | 0.85 | KDM4E (0.31) | ALDH1A1KDM4ESMN1; SMN2TDP1 | |
| SCHEMBL20126630 | 0.85 | KDM4E (0.31) | ALDH1A1KDM4ESMN1; SMN2TDP1 | |
| SCHEMBL17351861 | 0.83 | GRIN2B (0.49) | ALDH1A1KDM4ESMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708335-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | Apytinyx Inc. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20150368254-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368254-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | ALDH1A1 2288/4885KDM4E 2649/4885SMN1; SMN2 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.